Background: Bhasma formulations in Rasashastra practice the metal and mineral processing of Shodhana and Maraṇa to produce nanostructured, biocompatible formulations with rejuvenating and carrier properties that resemble contemporary drug ideas.
Methods: Narrative synthesis of literature from classical texts, pharmacopeial and current standards in PubMed, Scopus, ScienceDirect, and AYUSH databases using keywords such as "Bhasma," "Rasashastra," "Swarna/JasadaBhasma," "nanoparticles," and "quality control." The literature studies given preference were those involving characterization, pharmacology, toxicology, and GMP of important Bhasmas.
Results: Authentic Bhasmas (particles sized 10-200 nm with a herbal matrix) exhibit increased bioavailability, immunomodulatory, antidiabetic, and neuroprotective properties based on preclinical and clinical trials. The safety of proper preparation is acknowledged, but there are still general safety loopholes and unsatisfactory product toxicity.
Conclusions: Bhasma is a traditional nanomedicine that needs an integrated quality control system, validated studies, and a globally integrated regulatory system-oriented approach while maintaining Ayurvedic principles.
Keywords: Ayurveda, Bhasma, Nanomedicine
How to cite this article: Rathod H, Rajput MH, Bhasma as Nanomedicine in Rasashastra: A Comprehensive, Critical Evaluation. Int J Drug Deliv Technol. 2026;16(1s): 501-504; DOI: 10.25258/ijddt.16.501-504